Added to YB: 2026-09-08
Pitch date: 2026-09-05
HROW [bullish]
Harrow, Inc.
Author Info
Value with a Catalyst covers long value oriented small and mid- cap investment ideas with a catalyst. Sign up for the newsletter.
Company Info
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States.
Market Cap
$1.4B
Pitch Price
N/A
Price Target
136.00 (+253%)
Dividend
N/A
EV/EBITDA
86.64
P/E
-38.57
EV/Sales
6.02
Sector
Pharmaceuticals
Category
growth
Exploring Harrow Health
HROW: Harrow’s medium-term case rests first on Melt, a non-opioid cataract-sedation product whose estimated $1.6B risk-adjusted value exceeds the current ~$1.5B market cap, with an NDA expected in 2027 and launch no earlier than 2028. The eye-care business could reach $140M of annual FCF as new products scale into an expanded cost base, but 2026 EBITDA guidance looks likely to fall; start below full size given near-term volatility.
Read full article (5 min)